Affymax Research Institute (AKA: Affymax Inc) Profile last edited on: 5/12/22
CAGE:
UEI:
Business Identifier: Blood & Coagulation Disorders & Products: Renal System
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Multiple
Congr. District: 18
County: Santa Clara
Congr. District: 18
County: Santa Clara
Public Profile
Affymax Research Institute was a drug discovery company that was acquired in March 1995, by Glaxo, now Glaxo Wellcome, one of the world's leading research-based pharmaceutical companies. The company continued to opperate as a subsidiary of Glaxo, until it went out of business in 2014. The company was a biopharmaceutical company, engaged in the development of drugs for the treatment of serious and life-threatening conditions. The company developed Hematide, which was in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. Affymax, Inc. had strategic alliance agreements with Takeda Pharmaceutical Company Limited and Nektar Therapeutics AL, Corporation to manufacture, develop, and commercialize Hematide
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
500+Revenue Range
Over 50MVC funded?
YesPublic/Private
Publicly TradedStock Info
OTC : AFFYIP Holdings
20-24Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 1996 | 2 | NIH | $825,000 | |
| Project Title: Rapid detection of HIV drug resistance | ||||
| 1995 | 1 | NIH | $98,709 | |
| Project Title: Treatment of B Cell Lymphomas with Synthetic Peptides | ||||
| 1993 | 2 | DOE | $550,000 | |
| Project Title: Spatially defined oligonucleaotide arrays | ||||
Key People / Management
Arlene M Morris -- President
Stephen P A Fodor
Stephen P A Fodor
